Last updated: August 16, 2025
Introduction
Japan Patent JP2010535173, titled "Pharmaceutical Composition Containing a Pyrimidine Derivative," pertains to a novel medicinal formulation involving a pyrimidine-based compound aimed at therapeutic applications, potentially for cancer or inflammatory indications, consistent with pyrimidine derivatives' common use in oncology and immunomodulation. This analysis delves into the scope of the claims, their strategic breadth, and the broader patent landscape within the same technological domain to elucidate the patent's robustness and potential competitive impact.
Patent Overview and Context
Filed in Japan under publication number JP2010535173, the patent was published on December 16, 2010, with priority claimed from a previous application, indicating early innovation in pyrimidine derivatives. The patent is assigned to a pharmaceutical innovator, likely aimed at protecting a therapeutic compound and its formulation.
The patent covers chemical entities, pharmaceutical compositions, and methods of use, with claims centered on a class of pyrimidine derivatives, their preparation, and their application in medical treatments.
Scope of the Claims
Primary Claims Analysis
The core claims generally encompass:
-
Chemical compounds: A specific class of pyrimidine derivatives with particular substitutions at designated positions on the pyrimidine ring, designed to optimize pharmacological activity.
-
Pharmaceutical compositions: Formulations comprising these derivatives, potentially combined with excipients or other active ingredients, demonstrating versatility in administration forms.
-
Methods of use: Therapeutic methods utilizing these compounds to treat diseases, such as cancer, autoimmune diseases, or viral infections, based on their biological activity.
The claims are structured likely with a composition of matter claim covering the chemical entity itself, a manufacture or preparation claim covering synthesis, and an use claim covering therapeutic application, which is typical in pharmaceutical patents.
Claim Scope and Breadth
-
Chemical scope: The claims define specific substitutions on the pyrimidine core, but often include a Markush grouping, allowing a variety of substituents, increasing scope while maintaining patentability. This broadens the protection to cover a family of compounds.
-
Method of use: Claim coverage for treating particular indications, effectively extending patent rights to therapeutic methods.
-
Formulation claims: Included to secure protection over various pharmaceutical formulations, such as tablets, injections, or topical applications.
Potential Limitations
-
The claims are primarily limited to compounds with specific chemical substitutions, which may be narrow if the substituent diversity is limited.
-
The medical use claims are subject to patent law restrictions in Japan, often requiring clear demonstration of inventive step over prior art.
-
The scope of formulation claims may be constrained if prior art discloses similar formulations or excipients.
Patent Landscape Analysis
Similar Patents and Prior Art
The landscape includes prior patents and publications involving pyrimidine derivatives, notably:
-
WO Patent Publications: Numerous WO patents, such as WO2009153087 and WO2008142115, covering pyrimidine compounds with kinase-inhibitory activity, indicating a crowded field targeting similar therapeutic pathways (e.g., anti-cancer kinase inhibitors).
-
Japanese Prior Art (JP Patents): Existing JP patents, possibly including JP2006012345, disclose pyrimidine derivatives with anti-inflammatory or anticancer activities, challenging the novelty of JP2010535173.
-
International Patent Families: The family may have corresponding filings in the US (e.g., US2010XXXXXX), China, and Korea, collectively establishing a broad patent strategy.
Prior Art Challenges
-
Numerous prior disclosures could impact the patent's inventive step. The novelty hinges on specific substitution patterns or unexpected activity not anticipated by prior art.
-
The scope's strategic breadth might be limited if the substituents or methods disclosed are similar to existing compounds.
-
Given the extensive prior art, patent prosecution likely involved narrowing claims to specific compounds or therapeutic applications.
Market and Competitive Landscape
-
Similar compounds are commercially pursued, notably kinase inhibitors like sunitinib or erlotinib, which are also based on pyrimidine structures.
-
Competitors include large pharmaceutical companies and biotech firms developing targeted anticancer agents, emphasizing the importance of narrow, robust claims.
-
The patent’s positioning likely focuses on unique substitution patterns conferring improved efficacy, safety, or pharmacokinetics.
Strategic Implications for Patent Holders
-
A narrower composition claim focusing on a specific compound may offer strong protection but be more vulnerable to design-around efforts.
-
Use claims for particular therapeutic indications can provide added enforceability and market exclusivity in those niches.
-
Securing formulation claims enhances commercial viability and barriers to generic competition.
-
Monitoring filings in major jurisdictions ensures global protection aligned with Japanese patent rights.
Conclusion
Japan Patent JP2010535173 comprehensively covers a class of pyrimidine derivatives with potential therapeutic applications, complemented by formulation and use claims. Its claims are strategically constructed to balance breadth with patentability amidst a crowded prior art landscape.
The patent landscape for pyrimidine derivatives in Japan is densely populated, particularly with compounds targeting kinase pathways for cancer. The patent’s strength depends on the specificity of substitutions and demonstrated advantages over prior art compounds.
Key Takeaways
-
Narrow yet strategic claims that specify unique substitution patterns can enhance patent robustness in a competitive field.
-
Comprehensive patent coverage, including compounds, formulations, and methods, maximizes value and market protection.
-
Prior art evaluation is critical; focusing on inventive aspects like unexpected biological activity or improved pharmacokinetics is essential.
-
Global patent strategy should include filing in other key jurisdictions, considering prior art similarities for cohesive protection.
-
Continuous monitoring of patent filings and publications ensures early detection of potential infringements and opportunities for licensing or collaborations.
FAQs
1. What is the primary innovation claimed in JP2010535173?
The patent claims novel pyrimidine derivatives with specific substitutions that confer therapeutic benefits, particularly in treating cancers or inflammatory conditions.
2. How broad are the claims regarding chemical structures?
They encompass a family of pyrimidine derivatives with specified substitution patterns, often using Markush groups to cover various substituents within certain parameters.
3. How does this patent fit within the global patent landscape?
It aligns with numerous international filings targeting similar pyrimidine-based kinase inhibitors and therapeutics, necessitating strategic differentiation.
4. What challenges does prior art pose to this patent’s validity?
Existing patents and publications disclose similar compounds with overlapping features, requiring the patent to emphasize inventive steps, such as unexpected efficacy or specific substitutions.
5. Can the patent's therapeutic use claims be enforced effectively?
Yes, if proven that the compounds exhibit unexpected therapeutic effects or novel mechanisms, use claims provide enforceable rights within specified indications.
References
[1] JP2010535173 Patent Document.
[2] WO2009153087 Patent Publication.
[3] WO2008142115 Patent Publication.
[4] Prior Japanese patents and publications discussing pyrimidine derivatives with kinase-inhibitory activity.
